VesCell

Hemostemix (HMTXF) closed the first tranche of a private placement, raising $461,230 by issuing 4,193,000 Units at $0.11 each. Each Unit includes a share and a warrant exercisable at $0.15. Proceeds fund working capital and VesCell marketing. Finder’s fees were paid, and certain directors participated, triggering related party considerations with MI 61-101 exemptions. The closing is subject to regulatory approval, and securities are subject to a four-month hold period. The offering introduces potential dilution from new shares and warrants.

Hemostemix (HMTXF) filed an FDA Pre-IND application for a Phase I basket trial of ACP-01 (VesCell™) to evaluate its safety and early efficacy across vascular dementia, peripheral arterial disease, angina, cardiomyopathy, and congestive heart failure. Hemostemix aims to use real-world evidence from Florida, where ACP-01 is available, to support regulatory advancement. The company has completed 498 safe treatments and has 11 peer-reviewed publications. The basket protocol seeks to accelerate development and expand target markets.